FY2025 · ended Dec 31, 2025 · Revenue $507.44M, +32.3% YoY · Filed Feb 23, 2026
GLAUKOS Corp (GKOS) files with the SEC under industry code 3841, Surgical & Medical Instruments & Apparatus. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $507.4 million and a net loss of $187.7 million. Free cash flow was -$22.5 million. As of Sep 30, 2026 it held $336.7 million in cash and investments and $105.1 million in total debt.
Revenue (TTM)
$690.33M
+46.9% vs year-ago TTM
Net income (TTM)
$-169.80M
-93.8% vs year-ago TTM
Operating cash flow (TTM)
$47.71M
+325.8% vs year-ago TTM
Free cash flow (TTM)
$36.02M
+230.5% vs year-ago TTM
EPS (TTM)
$-2.91
-88.3% vs year-ago TTM
Dividend per share
None
Shares outstanding
58.08M
+2.7% vs prior year
Net cash
$231.55M
as of Sep 30, 2026
Operating margin
-25.5%
FY 2026
Company profile
- Industry
- Surgical & Medical Instruments & Apparatus (SIC 3841)
- Listed as
- GKOS (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Aliso Viejo, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1192448
Other Surgical & Medical Instruments & Apparatus companies
- Stryker Corp SYK
- 3M Co MMM
- Boston Scientific Corp BSX
- Becton Dickinson & Co BDX
- Medline Inc. MDLN
- Resmed Inc RMD
- Dexcom Inc DXCM
- Fresenius SE & Co. KGaA FSNUY
All 151 Surgical & Medical Instruments & Apparatus companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $507.4M | $383.5M | $314.7M | $282.9M | $294.0M |
| Operating income | -$199.6M | -$122.4M | -$128.7M | -$82.3M | -$32.9M |
| Net income | -$187.7M | -$146.4M | -$134.7M | -$99.2M | -$49.6M |
| Diluted EPS | -$3.28 | -$2.77 | -$2.78 | -$2.09 | -$1.07 |
| Operating cash flow | -$14.8M | -$61.3M | -$57.8M | -$33.1M | $24.7M |
| Free cash flow | -$22.5M | -$67.6M | -$78.0M | -$63.3M | -$23.1M |
| Total assets | $893.5M | $974.8M | $940.4M | $1.0B | $1.0B |
| Total liabilities | $237.3M | $207.8M | $478.6M | $472.4M | $462.5M |
| Stockholders' equity | $656.2M | $766.9M | $461.8M | $530.0M | $587.2M |
| Cash and investments | $278.8M | $318.9M | $295.4M | $352.7M | $414.1M |
| Total debt | $106.5M | $105.9M | $103.2M | $101.5M | $103.4M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Oct 28, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Oct 28, 2026 | Oct 28, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Aug 3, 2026 | Aug 3, 2026 |
| 10-Q | Quarterly report | Jul 29, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Jul 29, 2026 | Jul 29, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 3, 2026 | May 28, 2026 |
All 1014 GLAUKOS Corp SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.